Skip to main content

Table 1 Systematic review of hydroxychloroquine use in osteoarthritis

From: Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial

Reference n Site Treatment Outcome
[23] 8 Erosive hand OA unresponsive to NSAIDs 200 mg HCQ 6/8 noted improvement in pain, reduced synovitis and reduced morning stiffness
     Response time 7/52 to 7/12. No adverse effects
[24] 15 Hand OA Placebo-controlled HCQ Improvement in clinical symptoms at 12 months (Ritchie index)
[25] 7 Erosive hand OA 200 to 400 mg HCG Improvement in 7/7 patients noted
[26] 15 Hand and knee OA HCQ 6/12 13/15 patients achieved good therapeutic response after 6 months
[27] 29 Knee OA 400 mg HCQ 4/12, placebo-controlled No difference in WOMAC pain (P = 0.551), stiffness (P = 0.512) or function (P = 0.293); no difference on VAS (P = 0.461) or Lequesne (P = 0.803) scales
[28] 88 Nodal OA of the hands HCQ 200 mg/bid, ACM 1.3 gm/tid or placebo 6/12 No significant difference between hydroxychloroquine, acetaminophen or placebo in mean number of tender joints at 24 weeks
[29] 8 Erosive or inflammatory OA HCQ 200 to 400 mg Clinical improvement in 5/8 patients, 3 patients discontinued (1 due to unresponsiveness, 2 due to side-effects)
[30]     Intra-articular chloroquine in RA and OA of knee joint
     No abstract available
  1. ACM, acetaminophen; HCQ, hydroxychloroquine; MeSH, medical subject headings; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Index of OA.